DOCSLIB.ORG

Phosphosignature™ ...From Cell Signaling Technology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phosphosignature™ ...From Cell Signaling Technology UNPARALLELED PRODUCT QUALITY, VALIDATION AND TECHNICAL SUPPORT PhosphoSignature™ ...from Cell Signaling Technology PhosphoScan® Profiling Table: SILAC Analysis of H3255 Cells Treated with Iressa www.cellsignal.com Study Background a high-resolution, high mass accuracy mass Select Column Descriptions: spectrometer. From this one sample, one LC- In many forms of non-small-cell lung cancer, Protein Accession Number: Unique protein MS analysis gave 930 phospho-tyrosine-peptide the receptor tyrosine kinase EGFR (epidermal identifier for parent protein from which the cor- assignments, corresponding to 234 phospho- growth factor receptor) is overexpressed. Iressa responding phospho-peptide is derived. Detailed tyrosine sites. This included 63 phospho- protein information for each identifier can be found (Gefitinib) is an EGFR inhibitor approved by tyrosine-peptide assignments to EGFR and 20 in PhosphoSitePlus® (www.phosphosite.org). the FDA for treatment of patients with advanced to the receptor tyrosine kinase Met. The effect of Phospho-Site (Tyr): The phosphorylated (tyro- disease, and the majority of patients who respond Iressa on the level of each phospho-tyrosine site sine) residue number in the protein sequence; the to Iressa treatment have tumors with mutant symbol § denotes a published site; all other sites was reflected in the ratio of normal- and heavy- EGFR genes (Lynch et al., 2004). The molecular are novel and were discovered in PhosphoScan® isotope labeled phosphopeptide ions. Iressa mechanisms underlying Iressa-responsiveness are studies performed by scientists at Cell Signaling treatment lowered the levels of 110 phospho- still largely unknown. Technology. tyrosine sites at least 2.5-fold, and several Phospho-peptide: Sequence assigned based on Study Description phospho-tyrosine sites in EGFR were at least 30- mass spectrometry analysis; y indicates the site(s) of tyrosine phosphorylation. For PhosphoScan® analysis (Guo et al., fold less abundant after Iressa treatment. Other 2007), quantification of Iressa-regulated phospho-tyrosine sites responding strongly to Count in Study: The number of times the phos- ® Iressa were found in the adaptor proteins DLG3 phopeptide was identified in this PhosphoScan phosphorylation was performed with SILAC, study. (Ong and Mann, 2006). Briefly the non-small- and Gab1 and the phospholipase PLCG1. Count at CST: The number of times the phospho- cell lung cancer cell line H3255 was grown in References peptide has been identified in all PhosphoScan® normal culture media, serum starved overnight, studies conducted at Cell Signaling Technology. Guo A, Villén J, Kornhauser J, Lee KA, Stokes and treated with 1 µM Iressa for 3 hours. To Heavy-to-Light Ratio: The ratio of heavy- and M, Rikova K, Possemato A, Nardone J, Innocenti produce an isotope-coded untreated control normal-isotope labeled phosphopeptide ions, re- G, Wetzel R, Wang Y, MacNeill J, Mitchell J, sample, H3255 was grown in media formulated sulting from SILAC labeling of Iressa-treated cells Gygi SP, Rush J, Polakiewicz RD, Comb MJ. to contain heavy isotope-labeled forms of with light-isotope-labeled forms of arginine and Signaling Networks Assembled by Oncogenic lysine. The ratios correspond to the fold-change arginine and lysine. The cells were harvested and in phosphopeptide levels due to Iressa treatment. 8 EGFR and c-Met. Proc Natl Acad Sci U S A. lysed (2 X 10 cells, corresponding to 10 mg Positive numbers indicate phosphopeptides that 2007, in press. cellular protein), and equal amounts of Iressa- are more abundant in untreated cells than in treated (normal isotope coded) and untreated Lynch TJ, Bell DW, Sordella R, Gurubhagavatula Iressa-treated cells. (heavy isotope coded) lysate were combined. S, Okimoto RA, Brannigan BW, Harris PL, The proteins were reduced and alkylated to Haserlat SM, Supko JG, Haluska FG, Louis stabilize cysteine-containing peptides, and DN, Christiani DC, Settleman J, Haber DA. the extract was digested with trypsin. The Activating mutations in the epidermal growth digested cellular protein extract was taken factor receptor underlying responsiveness of non- through the PhosphoScan® procedure using small-cell lung cancer to gefitinib.N Engl J Med. the phospho-tyrosine antibody P-Tyr-100 to 2004 May 20;350(21):2129-39. isolate phospho-tyrosine-containing peptides. Ong SE, Mann M. A practical recipe for stable The isolated peptides were analyzed by liquid isotope labeling by amino acids in cell culture chromatography-mass spectrometry using (SILAC). Nat. Protoc. 2006;1(6):2650-60. Cytoskeletal protein Other 9% 34% Total peptides = 930 (see pie chart) Total non-redundant sites = 251 Total proteins = 183 Adhesion 11% Adaptor/scaffold Protein kinase, Tyr 13% Protein kinase, 19% Ser/Thr 14% 2 PHOspHOSCAN-SILAC ANalysis OF H3255 Cells TreateD WitH Iressa Count Count Heavy-to-Light Ratio Gene Name Description Accession kD Site Peptide in Study at CST Mean Range Actin binding proteins CTNNA1 Catenin alpha-1 (Cadherin-associated protein) P35221 100 177 NAGNEQDLGIQyK 4 282 1.6 1.5-1.8 CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 248 YRPSMEGyR 2 44 14.5 7.2-21.9 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 865 SQSSHSyDDSTLPLIDR 1 21 3.9 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 904 SLDNNySTPNERGDHNR 1 224 5.5 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 904 SLDNNySTPNER 4 1198 3.0 2.8-3.1 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 §228 HYEDGYPGGSDNyGsLSR 4 4 1.8 1.8-1.9 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 §228 HYEDGYPGGSDNyGSLSR 6 754 1.8 1.7-1.9 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 §257 QDVyGPQPQVR 1 482 1.1 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 §280 FHPEPyGLEDDQR 3 109 6.1 3.8-10.5 substrate) (p120(cas)) CTNND1 Catenin delta-1 (Cadherin-associated Src O60716 108 §96 LNGPQDHSHLLySTIPR 1 400 3.0 substrate) (p120(cas)) DBNL Drebrin-like protein (SH3 domain-containing Q9UJU6 48 §162 FQDVGPQAPVGSVyQK 2 511 11.1 7.3-14.9 protein 7) (HIP-55) Adaptor/scaffold proteins ANK3 Ankyrin-3 (ANK-3) (Ankyrin-G) Q12955 480 533 ADIVQQLLQQGASPNAATTSGyTPLHLSAR 3 163 0.7 0.6-0.8 NEDD9 Enhancer of filamentation 1 (CRK-associated Q14511 93 §166 TGHGYVyEYPSR 4 325 1.2 1.1-1.3 substrate-related protein)(CasL) CRK Proto-oncogene C-crk (p38) (Adapter molecule P46108 34 136 QGSGVILRQEEAEyVR 1 2 9.9 crk) CRK Proto-oncogene C-crk (p38) (Adapter molecule P46108 34 136 QEEAEyVR 1 6 >8.4 crk) DLG3 Disks large homolog 3 (Synapse-associated Q92796 90 673 RDNEVDGQDyHFVVSR 7 597 >58.4 >27.9-65.2 protein 102) (SAP102) DLG3 Disks large homolog 3 (Synapse-associated Q92796 90 673 DNEVDGQDyHFVVSR 3 67 25.5 18.1-33.5 protein 102) (SAP102) EPS8 Epidermal growth factor receptor kinase substrate Q12929 92 §485 LSTEHSSVSEyHPADGYAFSSNIYTR 2 43 19.9 17.0-22.9 8 FLOT1 Flotillin-1 O75955 47 203 VSAQyLSEIEMAK 3 116 1.3 1.2-1.3 GAB1 GRB2-associated-binding protein 1 (GRB2- Q13480 77 §406 DASSQDCyDIPR 2 937 13.9 9.2-18.5 associated binder 1) GAB1 GRB2-associated-binding protein 1 (GRB2- Q13480 77 §627 GDKQVEyLDLDLDSGK 4 272 >11.0 >5.9->16.7 associated binder 1) GAB1 GRB2-associated-binding protein 1 (GRB2- Q13480 77 §659 SSGSGSSVADERVDyVVVDQQK 3 807 >22.0 >6.6->51.9 associated binder 1) ITSN2 Intersectin-2 (SH3 domain-containing protein 1B) Q9NZM3 193 §552 LIyLVPEK 2 335 8.7 7.8-9.5 (SH3P18) WASL Neural Wiskott-Aldrich syndrome protein (N- O00401 55 §256 VIyDFIEK 2 593 1.0 1.0-1.1 WASP) PAG1 Phosphoprotein associated with glycosphingolipid- Q9NWQ8 47 §227 AEFAEyASVDR 4 340 1.6 1.5-1.7 enriched microdomains 1 PAG1 Phosphoprotein associated with glycosphingolipid- Q9NWQ8 47 §341 SGQSLTVPESTyTSIQGDPQR 1 413 3.2 enriched microdomains 2 PAG1 Phosphoprotein associated with glycosphingolipid- Q9NWQ8 47 §359 SPSSCNDLyATVK 4 432 2.6 2.0-3.2 enriched microdomains 3 PAG1 Phosphoprotein associated with glycosphingolipid- Q9NWQ8 47 §417 ATLGTNGHHGLVPKENDyESISDLQQGR 4 184 >10.4 >6.0-13.9 enriched microdomains 4 PAG1 Phosphoprotein associated with glycosphingolipid- Q9NWQ8 47 §417 ENDyESISDLQQGR 4 578 3.2 3.0-3.4 enriched microdomains 5 PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 388 FSPDSQyIDNR 2 228 1.7 1.5-1.8 isotype-specific-interacting prot) 3 LEGEND: § published site * phosphorylation site # oxidized methionine SUMMARY TABLE PHOspHOSCAN-SILAC ANalysis OF H3255 Cells TreateD WitH Iressa Count Count Heavy-to-Light Ratio Gene Name Description Accession kD Site Peptide in Study at CST Mean Range PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 489 DVTIGGSAPIyVK 4 146 1.3 1.2-1.4 isotype-specific-interacting prot) PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 719 RISHSLySGIEGLDESPSR 1 67 1.4 isotype-specific-interacting prot) PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 719 ISHSLySGIEGLDESPSR 5 150 0.9 0.7-1.1 isotype-specific-interacting prot) PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 719 RIsHSLySGIEGLDESPSR 2 2 0.3 0.3-0.4 isotype-specific-interacting prot) PARD3 Partitioning-defective 3 homolog (Atypical PKC Q8TEW0 151 §1127 EGHMMDALyAQVK 1 63 0.8 isotype-specific-interacting prot) MPZL1 Myelin protein zero-like protein 1 O95297 29 §263 SESVVyADIR 3 449 2.1 2.1-2.2 DLG1 Disks large homolog 1 (Synapse-associated Q12959 100 760 DyHFVTSR 1 15 1.5 protein 97) (SAP-97) (hDlg) DLG1
Load more

Recommended publications
  • Eradication of ENO1-Deleted Glioblastoma Through Collateral Lethality
    bioRxiv preprint doi: https://doi.org/10.1101/331538; this version posted May 25, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Eradication of ENO1-deleted Glioblastoma through Collateral Lethality Yu-Hsi Lin1, Nikunj Satani1,2, Naima Hammoudi1, Jeffrey J. Ackroyd1, Sunada Khadka1, Victoria C. Yan1, Dimitra K. Georgiou1, Yuting Sun3, Rafal Zielinski4, Theresa Tran1, Susana Castro Pando1, Xiaobo Wang1, David Maxwell5, Zhenghong Peng6, Federica Pisaneschi1, Pijus Mandal7, Paul G. Leonard8, Quanyu Xu,9 Qi Wu9, Yongying Jiang9, Barbara Czako10, Zhijun Kang10, John M. Asara11, Waldemar Priebe4, William Bornmann12, Joseph R. Marszalek3, Ronald A. DePinho13 and Florian L. Muller#1 1) Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 2) Institute of Stroke and Cerebrovascular Disease, The University of Texas Health Science Center at Houston, TX 77030 3) Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 4) Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 5) Institutional Analytics & Informatics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 6) Cardtronics, Inc., Houston, TX 77042 7) Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 bioRxiv preprint doi: https://doi.org/10.1101/331538; this version posted May 25, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Apoptotic Genes As Potential Markers of Metastatic Phenotype in Human Osteosarcoma Cell Lines
    17-31 10/12/07 14:53 Page 17 INTERNATIONAL JOURNAL OF ONCOLOGY 32: 17-31, 2008 17 Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines CINZIA ZUCCHINI1, ANNA ROCCHI2, MARIA CRISTINA MANARA2, PAOLA DE SANCTIS1, CRISTINA CAPANNI3, MICHELE BIANCHINI1, PAOLO CARINCI1, KATIA SCOTLANDI2 and LUISA VALVASSORI1 1Dipartimento di Istologia, Embriologia e Biologia Applicata, Università di Bologna, Via Belmeloro 8, 40126 Bologna; 2Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; 3IGM-CNR, Unit of Bologna, c/o Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy Received May 29, 2007; Accepted July 19, 2007 Abstract. Metastasis is the most frequent cause of death among malignant primitive bone tumor, usually developing in children patients with osteosarcoma. We have previously demonstrated and adolescents, with a high tendency to metastasize (2). in independent experiments that the forced expression of Metastases in osteosarcoma patients spread through peripheral L/B/K ALP and CD99 in U-2 OS osteosarcoma cell lines blood very early and colonize primarily the lung, and later markedly reduces the metastatic ability of these cancer cells. other skeleton districts (3). Since disseminated hidden micro- This behavior makes these cell lines a useful model to assess metastases are present in 80-90% of OS patients at the time the intersection of multiple and independent gene expression of diagnosis, the identification of markers of invasiveness signatures concerning the biological problem of dissemination. and metastasis forms a target of paramount importance in With the aim to characterize a common transcriptional profile planning the treatment of osteosarcoma lesions and enhancing reflecting the essential features of metastatic behavior, we the prognosis.
    [Show full text]
  • Rabbit Mab A
    Revision 1 C 0 2 - t Enolase-2 (D20H2) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 1 7 Web: [email protected] 1 www.cellsignal.com 8 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP H M R Mk Endogenous 47 Rabbit IgG P09104 2026 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity Enolase-2 (D20H2) Rabbit mAb recognizes endogenous levels of total enolase-2 protein. May cross-react with exogenous levels of enolase-1. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human enolase-2 protein. Background Enolase is a glycolytic enzyme that is involved in the conversion of 2-phosphoglycerate to phosphoenolpyruvate (1). Mammalian enolase has three subunits: α, β, and γ, that can form homo and heterodimers. Homodimers of γ enolase are neuronal-specific (2). Research studies have shown elevated levels of neuro-specific enolase-2 in neuroblastoma (2) and small-cell lung cancer (3,4). 1. Van Obberghen, E. et al. (1988) J Neurosci Res 19, 450-6. 2.
    [Show full text]
  • Neuron Specific Enolase (NSE) ELISA Kit
    Package Insert Neuron Specific Enolase (NSE) ELISA Kit Catalog Number: NSE31-K01 (1 x 96 wells) For Research Use Only. Not for use in diagnostic procedures. v. 1.0 Eagle Biosciences, Inc. 20A Northwest Blvd., Suite 112, Nashua, NH 03063 Phone: 617-419-2019 Fax: 617-419-1110 www.EagleBio.com INTENDED USE The Eagle Biosciences Human Neuron Specific Enolase (NSE) ELISA Assay Kit (enzyme-linked immunoassay kit) is intended for the quantitative determination of human neuron specific enolase (NSE) levels in serum. The Eagle Biosciences Human Neuron Specific (NSE) ELISA Assay Kit is for research use only and not to be used in diagnostic procedures. INTRODUCTION The glycolytic enzyme enolase (2-phospho-D-glycerate hydrolyase) exists as several dimeric isoenzymes (αα, αβ, ββ and γγ) composed of three distinct subunits: α, β, and γ. Three isoenzymes are found in human brain: αα, αβ, and γγ. The heterologous αγ-isoenzyme and the homologous γγ -enolase isoenzymes are known as neuron-specific enolase (NSE) as these isoenzymes initially were detected in neurons and neuroendocrine cells. By using monoclonal antibodies specific to the γ-subunit of the enzyme allow the test to detect both the αγ and the γγ forms. The NSE levels are quite low in normal healthy people and in people with benign disease. Lung cancer is one of the most common cancer forms with incidences about 50-100 per 100,000 population. Approximately 20% of the lung cancer is small cell lung cancer. NSE has been shown to be a valuable tumor marker of neuroendocrine origin, particularly in small cell lung cancer and in neuroblastoma.
    [Show full text]
  • In-Depth Proteomic Analysis of Tissue Interstitial Fluid for Hepatocellular Carcinoma Serum Biomarker Discovery
    FULL PAPER British Journal of Cancer (2017) 117, 1676–1684 | doi: 10.1038/bjc.2017.344 Keywords: biomarker; tissue interstitial fluid; hepatocellular carcinoma; proteomics; prognosis In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery Jian Zhang1, Ning Hao1, Wei Liu2, Min Lu3, Longqin Sun1, Ning Chen1, Miantao Wu4, Xiaohang Zhao5, Baocai Xing2,7, Wei Sun*,1,7 and Fuchu He*,1,6,7 1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Beijing Institute of Radiation Medicine, Beijing 102206, China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery I, Peking University Cancer Hospital and Institute, Beijing 100036, China; 3Department of Pathology, School of Basic Medical Sciences, Peking University, Beijing 100191, China; 4State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; 5State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China and 6Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China Background: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. New serum biomarkers for HCC screening are needed, especially for alpha-fetoprotein (AFP) negative patients. As a proximal fluid between body fluids and intracellular fluid, tissue interstitial fluid (TIF) is a suitable source for serum biomarker discovery. Methods: Sixteen paired TIF samples from HCC tumour and adjacent non-tumour tissues were analysed by isobaric tags for relative and absolute quantitation (iTRAQ) method.
    [Show full text]
  • (NSE) ELISA Kit Cat. #. EK-0050
    ELISA kits available from GSI (see details at the web site) #EK-0010 Human Leptin Instruction Manual No. M-EK-0050 # EK-0700 Human Sex Hormone Binding Glob (SHBG) # EK-0900 Human IGF-Binding Protein 1 (IGFBP1) # EK-1000 Human C-Reactive Protein (CRP) # EK-1190 Human Serum Albumin # EK-1200 Human Albumin (Urinary) Human Neuron Specific Enolase (NSE) # EK-1750 Human IgG (total) # EK-1760 Human IgM # EK-1800 Human IgE # EK-1810 Human Ferritin # EK-1210 Human Transferrin (Tf) # EK-0020 Beta-2 microglobulin ELISA Kit Cat. #. EK-0050 # EK-1600 Human Growth Hormone (GH) # EK-0060 Human Pancreatic Colorectal cancer (CA-242) # EK-1820 Human Ovarian Cancer (CA125) # EK-1830 Human CA153 For Quantitative Determination of # EK-1840 Human Pancreatic & GI Cancer (CA199) # EK-1310 Human Pancreatic Lipase Neuron specific enolase In Human Serum # EK-1400 Human Prostatic Acid Phosphatase (PAP) # EK-1500 Human Prostate Specific Antigen (PSA) # EK-1510 free PSA (fPSA) # EK-0500 Human Alpha Fetoprotein (AFP) # EK-0050 Human Neuron Specific Enolase (NSE) For In Vitro Research Use Only # EK-0030 Human Insulin # EK-0040 Human C-peptide # EK-0100 Human Luteinizing Hormone (LH) # EK-0200 Human Follicle Stimulating Hormone (FSH) # EK-0300 Human Prolactin (PRL) # EK-0400 Human Chorionic Gonadotropin (HCG) # EK-0410 HCG-free beta # EK-0600 Human Thyroid Stimulating Hormone (TSH) # EK-1100 Human Total Thyroxine (T4) # EK-1110 Human Free T4 (fT4) # EK-1650 Human free triiodothyronine (fT3) # EK-1700 Human T3 (total) # EK-1850 Human Cortisol # EK-1860 Human Progesterone # EK-1865 Human Pregnolone # EK-1875 Human Aldosterone # EK-1880 Human Testosterone # EK-1885 Human free Testosterone # EK-1910 Human Androstenedione # EK-1920 Human Estradiol # EK-1925 Human Estrone # EK-1940 Dihydrotestosterone (DHT) # EK-1950 Human DHEA-sulphate (DHEA-S) # EK-3400 Human serum Neopterin] # EK-3000 Human Rheumatoid Factors IgM (RF) # EK-3100 Human anti-dsDNA # EK-3200 Anti-Nuclear Antibodies (ANA) Page 7 EK-0050 (ub61222A) Human Neuron Specific Enolase (NSE) ELISA KIT PERFORMANCE CHARACTERISTICS Cat.
    [Show full text]
  • Datasheet (Pdf)
    alpha-Enolase/Enolase 1 Data Sheet Catalog Number: MO22153 Host: Mouse Product Type: Monoclonal IgG1 Species Rat Affinity Purified Antibody Reactivity: Immunogen Sequence: N-terminal 12 amino acids of bovine Format: Liquid, 100 ul aliquot enolase 1 Concentration: 1 mg/ml HGNC name for this protein is ENO1 Applications: Immunofluorescence/Immunocytochemistry: 1:2,000-5,00 Immunohistochemistry: 1:2,000-5,000 Western Blot: 1:5,000-10,000 Dilutions listed as a recommendation. Optimal dilution should be determined by investigator. Storage: Antibody can also be aliquoted and stored frozen at -20° C to -70° C in a manual defrost freezer for six months without detectable loss of activity. The antibody can be stored at 2° - 8° C for 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles. Application Notes Description/Data: Enolase 1 or α is also known as non-neuronal enolase (NNE) and is expressed in most kinds of tissue, but is absent from neurons. Abnormal expression of NNE is associated with tumor progression in some breast and head and neck cancer (1, 2). Enolase 2 or γ is also known as neuron specific enolase (NSE), (We offer Neuron Specific Enolase (NSE)). A switch from NNE to NSE occurs in the development of neurons (3). Enolase 3 or β is expressed primarily in muscle cells. Monoclonal antibody MO22153 was raised against the N-terminal 12 amino acids of bovine enolase 1 which was synthesized on a 8-amine lysine core using the multiple antigen presentation method. The antibody was tested for binding to expressed bovine enolase 1, 2 and 3 and shown to be specific for only enolase 1.
    [Show full text]
  • Human Neuron Specific Enolase (NSE) ELISA Kit Cat. #. 0050
    ELISA kits available from ADI (see details at the web site) #0010 Human Leptin Instruction Manual No. M-0050 #200-120-AGH Human globular Adiponectin (gAcrp30) #0700 Human Sex Hormone Binding Glob (SHBG) #0900 Human IGF-Binding Protein 1 (IGFBP1) Human Neuron Specific Enolase (NSE) #1000 Human C-Reactive Protein (CRP) #100-110-RSH Human Resistin /FIZZ3 #100-140-ADH Human Adiponectin (Acrp30) ELISA Kit Cat. #. 0050 #100-160-ANH Human Angiogenin #100-180-APH Human Angiopoietin-2 (Ang-2) #100-190-B7H Human Bone Morphogenic Protein 7 (BMP-7) For Quantitative Determination of #1190 Human Serum Albumin #1200 Human Albumin (Urinary) Neuron specific enolase In Human Serum #1750 Human IgG (total) #1760 Human IgM #1800 Human IgE #1810 Human Ferritin #1210 Human Transferrin (Tf) #0020 Beta-2 microglobulin #1600 Human Growth Hormone (GH) #0060 Human Pancreatic Colorectal cancer (CA-242) #1820 Human Ovarian Cancer (CA125) #1830 Human CA153 #1840 Human Pancreatic & GI Cancer (CA199) #1310 Human Pancreatic Lipase #1400 Human Prostatic Acid Phosphatase (PAP) #1500 Human Prostate Specific Antigen (PSA) #1510 free PSA (fPSA) #0500 Human Alpha Fetoprotein (AFP) #0050 Human Neuron Specific Enolase (NSE) #0030 Human Insulin #0040 Human C-peptide #0100 Human Luteinizing Hormone (LH) #0200 Human Follicle Stimulating Hormone (FSH) For In Vitro Research Use Only #0300 Human Prolactin (PRL) #0400 Human Chorionic Gonadotropin (HCG) #0410 HCG-free beta #0600 Human Thyroid Stimulating Hormone (TSH) #1100 Human Total Thyroxine (T4) #1110 Human Free T4 (fT4) #1650 Human free triiodothyronine (fT3) #1700 Human T3 (total) #1850 Human Cortisol #1860 Human Progesterone India Contact: #1865 Human Pregnolone #1875 Human Aldosterone Life Technologies (India) Pvt.
    [Show full text]
  • Proteome Profiler Human XL Oncology Array Kit Is a Rapid, Sensitive, and Economical Tool to Detect Differences in Cancer-Related Proteins Between Samples
    Proteome ProfilerTM Array Human XL Oncology Array Kit Catalog Number ARY026 For the parallel determination of the relative levels of selected human cancer-related proteins. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................1 TECHNICAL HINTS .................................................................................................................................................................1 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................2 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 SUPPLIES REQUIRED FOR CELL LYSATE SAMPLES ...................................................................................................3 SUPPLIES REQUIRED FOR TISSUE LYSATE SAMPLES ...............................................................................................3 SAMPLE COLLECTION & STORAGE .................................................................................................................................4
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • (ENO2, G-Enolase) Expression in Breast Cancer
    Soh et al. Cancer Cell International 2011, 11:41 http://www.cancerci.com/content/11/1/41 PRIMARYRESEARCH Open Access Arsenic, cadmium and neuron specific enolase (ENO2, g-enolase) expression in breast cancer Maureen A Soh1, Scott H Garrett1, Seema Somji1, Jane R Dunlevy2, Xu Dong Zhou1, Mary Ann Sens1, Chandra S Bathula1, Christina Allen1 and Donald A Sens1* Abstract Background: Neuron specific enolase (ENO2, g-enolase) has been used as a biomarker to help identify neuroendocrine differentiation in breast cancer. The goal of the present study was to determine if ENO2 expression in the breast epithelial cell is influenced by the environmental pollutants, arsenite and cadmium. Acute and chronic exposure of MCF-10A cells to As+3 and Cd+2 sufficient to allow colony formation in soft agar, was used to determine if ENO2 expression was altered by these pollutants. Results: It was shown that both As+3 and Cd+2 exposure caused significant increases in ENO2 expression under conditions of both acute and chronic exposure. In contrast, ENO1, the major glycolytic enolase in non-muscle and neuronal cells, was largely unaffected by exposure to either As+3 or Cd+2. Localization studies showed that ENO2 in the MCF-10A cells transformed by As+3 or Cd+2 had both a cytoplasmic and nuclear localization. In contrast, ENO1 was localized to the cytoplasm. ENO2 localized to the cytoplasm was found to co-localized with ENO1. Conclusion: The results are the first to show that ENO2 expression in breast epithelial cells is induced by acute and chronic exposure to As+3 or Cd+2.
    [Show full text]